Clinical Trial Update: A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A phase II trial evaluating anlotinib in combination with tislelizumab and AT as neoadjuvant therapy for triple-negative breast cancer is reported as phase II w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• AT
• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sichuan Provincial People's Hospital | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN